These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. Streba LA; Vere CC; Rogoveanu I; Streba CT World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859 [TBL] [Abstract][Full Text] [Related]
9. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Degasperi E; Colombo M Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):156-164. PubMed ID: 28404072 [TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Younossi Z; Stepanova M; Ong JP; Jacobson IM; Bugianesi E; Duseja A; Eguchi Y; Wong VW; Negro F; Yilmaz Y; Romero-Gomez M; George J; Ahmed A; Wong R; Younossi I; Ziayee M; Afendy A; Clin Gastroenterol Hepatol; 2019 Mar; 17(4):748-755.e3. PubMed ID: 29908364 [TBL] [Abstract][Full Text] [Related]
11. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Kanwal F; Kramer JR; Mapakshi S; Natarajan Y; Chayanupatkul M; Richardson PA; Li L; Desiderio R; Thrift AP; Asch SM; Chu J; El-Serag HB Gastroenterology; 2018 Dec; 155(6):1828-1837.e2. PubMed ID: 30144434 [TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma in non-alcohol fatty liver disease - changing trends and specific challenges. Berkan-Kawińska A; Piekarska A Curr Med Res Opin; 2020 Feb; 36(2):235-243. PubMed ID: 31631714 [No Abstract] [Full Text] [Related]
13. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period. Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208 [TBL] [Abstract][Full Text] [Related]
16. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Wong CR; Njei B; Nguyen MH; Nguyen A; Lim JK Aliment Pharmacol Ther; 2017 Dec; 46(11-12):1061-1069. PubMed ID: 28960360 [TBL] [Abstract][Full Text] [Related]
17. Obesity, non-alcoholic fatty liver disease and hepatocellular carcinoma: current status and therapeutic targets. Chen Y; Wang W; Morgan MP; Robson T; Annett S Front Endocrinol (Lausanne); 2023; 14():1148934. PubMed ID: 37361533 [TBL] [Abstract][Full Text] [Related]
18. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan. Tokushige K; Hashimoto E; Kodama K J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711 [TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment. Argyrou C; Moris D; Vernadakis S J BUON; 2017; 22(1):6-20. PubMed ID: 28365930 [TBL] [Abstract][Full Text] [Related]
20. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification. Ioannou GN; Green P; Kerr KF; Berry K J Hepatol; 2019 Sep; 71(3):523-533. PubMed ID: 31145929 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]